1. Pomerantz LLP is investigating Nektar for potential securities fraud. 2. Recent trial results for rezpegaldesleukin were statistically insignificant. 3. Nektar's stock fell 7.77% following the negative trial news. 4. The investigation aims to protect investor rights amid alleged misconduct. 5. Nektar's leadership may face scrutiny due to this situation.
FAQ
Why Very Bearish?
The significant stock price drop and ongoing investigation indicate loss of investor confidence. Historical cases show similar events led to long-term declines in stock value.
How important is it?
The investigation and negative trial results directly affect Nektar's reputation and stock price. Given the firm's focus on investor protection, this analysis holds substantial weight.
Why Short Term?
Immediate investor reaction to negative news is likely to continue impacting stock. Similar situations have shown a rapid market reaction but may stabilize over time.
Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Nektar Therapeutics (NKTR) Investors
NEW YORK, Dec. 30, 2025 — Pomerantz LLP has initiated an investigation into possible claims involving investors of Nektar Therapeutics (NASDAQ: NKTR). Investors are urged to reach out to Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 7980 for more information.
Background of the Investigation
The investigation by Pomerantz focuses on allegations that Nektar and certain members of its leadership may have engaged in securities fraud or other illicit business practices. This inquiry comes after significant news regarding Nektar’s clinical trials.
Recent Developments
On December 16, 2025, Nektar Therapeutics released a press statement announcing the topline results from the 36-week induction treatment period of their Phase 2b clinical trial, known as the REZOLVE-AA trial. This trial investigated the efficacy of investigational drug rezpegaldesleukin, identified as a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator. However, the announcement revealed that the trial had failed to achieve statistical significance.
Nektar attributed the disappointing results partly to the inclusion of four patients who were reportedly ineligible for participation in the trial. Following this disclosure, the company’s stock price plummeted by $4.14 per share, representing a significant 7.77% decline, closing at $49.16 per share on the same day.
About Pomerantz LLP
Pomerantz LLP, recognized as a leading firm in corporate, securities, and antitrust class action litigation, has a longstanding history of advocating for victims of securities fraud and corporate misconduct. Founded by the late Abraham L. Pomerantz, widely regarded as a pioneer in the field, the firm has consistently fought for investors’ rights for over 85 years.
The firm has successfully recovered numerous multimillion-dollar damages on behalf of class action members, directly impacting the integrity of securities markets.
Contact Information
Investors who believe they may have claims against Nektar Therapeutics are encouraged to contact:
- Danielle Peyton
- Pomerantz LLP
- Email: dpeyton@pomlaw.com
- Phone: 646-581-9980, ext. 7980
For more information regarding joining the class action, please visit the Pomerantz website at www.pomlaw.com.